1. BCMA-Targeted Biologic Therapies: The Next Standard of Care in Multiple Myeloma Therapy

   • Barry Paul
   • Cesar Rodriguez
   • Saad Z. Usmani

   Leading Article 12 April 2022 Pages: 613 - 631

   

2. Benefits and Harms of ‘Smart Drugs’ (Nootropics) in Healthy Individuals

   • Fabrizio Schifano
   • Valeria Catalani
   • Amira Guirguis

   Review Article 02 April 2022 Pages: 633 - 647

3. Targeting Acquired and Intrinsic Resistance Mechanisms in Epidermal Growth Factor Receptor Mutant Non-Small-Cell Lung Cancer

   • Manan P. Shah
   • Joel W. Neal

   Review Article 12 April 2022 Pages: 649 - 662

   

4. Pharmacological Treatment for Pedophilic Disorder and Compulsive Sexual Behavior Disorder: A Review

   • Valdemar Landgren
   • Josephine Savard
   • Christoffer Rahm

   Review Article Open access 12 April 2022 Pages: 663 - 681

   

5. Daratumumab: A Review in Newly Diagnosed Systemic Light Chain Amyloidosis

   • Hannah A. Blair

   Adis Drug Evaluation 13 April 2022 Pages: 683 - 690

   

6. Gefapixant: First Approval

   • Anthony Markham

   AdisInsight Report 28 March 2022 Pages: 691 - 695

   

7. Clazosentan: First Approval

   • Arnold Lee

   AdisInsight Report 01 April 2022 Pages: 697 - 702

   

8. Tebentafusp: First Approval

   • Sohita Dhillon

   AdisInsight Report 01 April 2022 Pages: 703 - 710

   

9. Palovarotene: First Approval

   • Sheridan M. Hoy

   AdisInsight Report 06 April 2022 Pages: 711 - 716

   

10. Correction to: Interchangeability of Biosimilars: Overcoming the Final Hurdles

    • Liese Barbier
    • Arnold G. Vulto

    Correction 07 April 2022 Pages: 717 - 717